Drug intelligence / Profile preview

IMT-103

Development stage: Preclinical
Lead developer: IMMUSE
Modality: Small Molecules

Overview

IMT-103 is an **IMMUSE** preclinical **small-molecule immunotherapy** being developed for **solid cancer**. Based on the company pipeline description, it is part of IMMUSE's small-molecule program focused on the **tumor microenvironment** and on reversing or modulating **dysfunctional and exhausted T-cell biology** in solid tumors. The specific molecular target has not been publicly disclosed, so the program is best characterized as a preclinical, target-undisclosed small-molecule immuno-oncology candidate for solid malignancies.

Beyond the preview

Go deeper on IMT-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMT-103.

Explore the full profile